Back

Human NLRP1 and NLRP3 interact driving inflammation in inflammosomopathies and inflammatory diseases

Suarez-Rivero, J. M.; Muela-Zarzuela, I.; Astorga-Gamaza, A.; Anton, R.; Bali, S.; Tamargo-Azpilicueta, J.; Guerra-Castellano, A.; De la Varga-Martinez, R.; Garcia-Cuesta, D.; Diaz-Moreno, I.; Joachimiak, L.; Oroz, J.; Sanz, A.; Cordero, M. D.

2026-01-29 immunology
10.64898/2026.01.26.701718 bioRxiv
Show abstract

Inflammasomes are multiprotein complexes that form and activate after exposure to pathogenic microbes and host danger signals that trigger an inflammatory response. Although NLRP1 and NLRP3 inflammasomes share structural similarities and can be activated by similar stimuli, no evidence of heterotypic inflammasome assemblies has been reported. Here, we identify a unique interaction between NLRP1 and NLRP3 in human cells, forming a hybrid inflammasome, to drive inflammation. NLRP1 is essential for this hydrid inflammasome activation and NLRP3-mediated Caspase-1 activation and release of IL-1{beta} and IL-18. The presence of the heterocomplex inflammasome was confirmed in blood samples from patients after kidney transplantation and is associated with inflammatory responses driven by NLRP3 and MEFV mutations that cause inflammasomopathies. Our findings reveal an unexpected level of intricacy in inflammasome composition, pinpointing hybrid targets that may pave the way for innovative pharmacological treatments for inflammatory disorders. Significance StatementPrevious findings showed interactions between NLRP3 and NLRC4 or NLRP3 and NLRP11 showing that would be possible the interaction of the inflammasomes as supercomplexes and not working alone. Now, we show a new inflammasome heterocomplex inflammasome between NLRP1 and NLRP3 which is associated to the inflammatory profile in autoimmune diseases patietns and transplanted patients. These findings could open a new research topic for the design of dual inflammasomes inhibitors.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Nature Immunology
71 papers in training set
Top 0.1%
18.1%
2
Immunity
58 papers in training set
Top 0.4%
12.0%
3
Nature Communications
4913 papers in training set
Top 20%
9.8%
4
Journal of Experimental Medicine
106 papers in training set
Top 0.2%
8.2%
5
Cell
370 papers in training set
Top 3%
6.2%
50% of probability mass above
6
Cell Reports
1338 papers in training set
Top 13%
3.8%
7
eLife
5422 papers in training set
Top 30%
3.0%
8
Science Immunology
81 papers in training set
Top 0.7%
3.0%
9
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 24%
2.8%
10
Cell Host & Microbe
113 papers in training set
Top 2%
2.3%
11
Science Advances
1098 papers in training set
Top 12%
2.3%
12
Nature
575 papers in training set
Top 9%
2.0%
13
Science Translational Medicine
111 papers in training set
Top 3%
1.6%
14
Science
429 papers in training set
Top 15%
1.6%
15
Neuron
282 papers in training set
Top 6%
1.6%
16
Journal of Clinical Investigation
164 papers in training set
Top 5%
1.2%
17
Cell Metabolism
49 papers in training set
Top 2%
1.2%
18
PLOS Biology
408 papers in training set
Top 14%
1.2%
19
Molecular Cell
308 papers in training set
Top 9%
0.9%
20
Frontiers in Immunology
586 papers in training set
Top 8%
0.7%
21
iScience
1063 papers in training set
Top 34%
0.7%
22
Advanced Science
249 papers in training set
Top 21%
0.7%
23
Nature Metabolism
56 papers in training set
Top 3%
0.6%